Skip to main content

Table 3 Characteristics of individual patients

From: Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation

TACE

Patient Number

Age

Gender

Etiology

AFP

# Tumors at Dx

Size (cm) pre-op

Within Milan

Pre-TACE Growth rate (cm/mo.)

Largest tumor dia by path

Days to Transplant*

Recur

Time to Recur

Reasons for TACE

A

B

T1

61

M

Cryptogenic

7254

1

6.3

N

N/A

5

241

N

 

X

 

T2

50

M

HCV

27.9

1

3.5

Y

0.02

3.7

327

Y

14.5mo.

 

X

T3

53

M

HCV

27.6

1

3.5

Y

N/A

5

263

N

  

X

T4

54

M

HCV

67

3

2.9, 1.6, 1

Y

N/A

3

153

N

  

X

T5

58

M

HCV

4

1

7.6

N

0

7.6

82

N

 

X

 

T6

59

M

HCV

4

2

3.1, 3.5

N

0.03

3.5

127

N

 

X

 

T7

65

F

HBV

667

1

2.5

Y

0.33

2.5

167

N

  

X

T8

68

F

HCV

18

1

6

N

N/A

4.7

174

N

 

X

 

T9

57

M

HCV

43

2

3.2, 1.8

N

N/A

3.2

141

N

 

X

 

T10

48

M

HCV

40

4

3.5, 2.8, 2.5, 1.0

N

0.23

3.5

190

Y

6mo.

X

 

T11

49

M

HCV

2000

1

3.5

Y

0.003

3.5

73

N

  

X

T12

53

M

HCV

189

3

2.4, 0.6, 0.3

Y

N/A

2.4

377

N

  

X

T13

54

M

HCV

8

5

2.1, 1.5, 1.4, 1, .7

N

0

4

241

N

 

X

 

T14

58

M

HCV

188

1

6.3

N

0.12

5.5

345

Y

13mo.

X

 

T15

57

M

HCV

3

3

2.8, 1.9, 1.3

Y

N/A

2

263

Y

18.5mo.

 

X

T16

62

M

HBV

20

2

1.7, 1.6

Y

0

2

153

N

  

X

  1. A = Downstage to achieve eligibility.
  2. B = Bridge to transplant.
  3. * = Days from HCC diagnosis to transplant.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us